Exelixis
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Exelixis sits in the top decile of US sponsors by registered trial count (#386 of 15,742 sponsors by registered trial count).
Exelixis: 48 sponsored US clinical trials, 8 recruiting.
Exelixis sponsors 48 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 17 completed. 11 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Renal Cell Carcinoma, with 4 trials.
Top-decile sponsor footprint
Exelixis ranks in the top decile of sponsors by registered trial count (#386 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (54.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
48 total, page 1 of 1
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07428616
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
NCT06962332
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010
Study of XB010 in Subjects With Solid Tumors
NCT06545331
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT05176483
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
NCT03690388
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06630247
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
NCT06191796
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
NCT05144347
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT04925284
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
NCT04726332
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
NCT01995058
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
NCT01908426
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
NCT01865747
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
NCT01761773
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
NCT01605227
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
NCT01522443
Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
NCT01493869
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
NCT01100619
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
NCT01068782
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
NCT00940225
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
NCT00960492
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
NCT00796484
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
NCT00704730
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
NCT00704288
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
NCT00596648
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
NCT00570635
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
NCT00595829
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
NCT00526838
A Safety Study of XL019 in Adults With Myelofibrosis
NCT00522574
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
NCT00464113
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
NCT00475917
Study of XL281 in Adults With Solid Tumors
NCT00451880
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
NCT00350831
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
NCT00215605
Study of XL820 in Adults With Solid Tumors
NCT00129571
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
NCT00234481
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 8 |
| Phase 3 | 11 |
Therapeutic Areas
What is open in the Exelixis pipeline
8 recruiting of 48 indexed (17% open); 17 completed (35%).
Phase mix: 11 late (III/IV) vs 37 early (I/II) (early-phase heavy).
Top condition: Renal Cell Carcinoma (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Exelixis: open-pipeline peers nationwide
Peers matched on 48 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Exelixis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 48 trials (± recruiting share)
- Albert Einstein Healthcare Network · 48 trials · 6% recruiting
- Sun Pharmaceutical Industries · 48 trials · 2% recruiting
- Walter Reed National Military Medical Center · 48 trials · 27% recruiting
- Alnylam Pharmaceuticals · 49 trials · 29% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Exelixis page
48 registered trials is a research-attention snapshot, not an endorsement of Exelixis or any single study.
- 8 of Exelixis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Renal Cell Carcinoma is the condition Exelixis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Renal Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Exelixis pipeline card: 48 registered trials from official public datasets.Report a data error.